Nautilus Biotechnology Inc Ordinary Shares NAUT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
-
Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
-
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
-
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
Trading Information
- Previous Close Price
- $2.44
- Day Range
- $2.17–3.02
- 52-Week Range
- $0.84–4.31
- Bid/Ask
- $2.82 / $2.86
- Shares Outstanding
- 127.37M
- Market Cap
- $367.77M
- Volume/Avg
- 39,624 / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 130
- Website
- https://www.nautilus.bio
Valuation
|
Metric
|
NAUT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.16 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NAUT
|
|---|---|
Quick Ratio | 8.87 |
Current Ratio | 9.25 |
Interest Coverage | — |
Quick Ratio
NAUT
Profitability
|
Metric
|
NAUT
|
|---|---|
Return on Assets (Normalized) | −30.20% |
Return on Equity (Normalized) | −37.11% |
Return on Invested Capital (Normalized) | −34.28% |
Return on Assets
NAUT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sZ$%F?m | LOCK|??m? | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#&##?T | LOCK|S$Zc% | $84B | |||
| Moderna Inc
MRNA
| LOCK|%$Hv!@? | LOCK|pl | $83B | |||
| argenx SE ADR
ARGX
| LOCK|!?r^%F | LOCK|S&? | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!N<!NxL | LOCK|V$% | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|d?P@?< | LOCK|$x>W | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|XxDZv!bp | LOCK|#TFr | $29B | |||
| Incyte Corp
INCY
| LOCK|gj#%%lm | LOCK|$$ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|QzMHMS | LOCK|fym | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?W%&!wm | LOCK|G>S | $14B |
United States